AI4Eyes

Machine learning and generative AI do the diagnostic work the product exists to perform. The company describes multimodal analysis of high resolution ocular surface imaging producing condition detection and personalized treatment recommendations, with the stated aim of consolidating ten gold standard dry eye tests into one exam lasting a few minutes. The patented hardware captures the data, but the diagnosis and treatment suggestion are model outputs; without them the device is a camera.

The workflow is explicitly clinician gated: AI delivers analysis, detection, and personalized treatment recommendations, and the company states clinicians approve results, after which the system learns and adapts. Describing an approval step as an integral stage of the loop rather than an afterthought is the right structure for software producing a diagnosis and treatment suggestion before the physician has seen the patient. Buyers should note the corollary that clinician approvals feed model adaptation, which makes approval quality a training input as well as a safety control.

The approach is described at a functional level, covering machine learning and generative AI applied to multimodal ocular surface imaging with a continuously learning loop, and the company has a stated partnership with a major academic machine learning institute to develop next generation applications. No model architecture, training data provenance, or performance metrics were located, which is the expected position for a company still pre commercial.

Evidence is in progress rather than published, and the company is transparent about that stage. A subdivision of Quebec's regional health agency is assessing image and annotation quality alongside the accuracy of the diagnostic and treatment recommendation algorithms, which is independent evaluation by a public health body rather than a vendor study. The company also cites the clinical problem specifically, that over 50 percent of people entering an eye clinic are affected by dry eye while only 8 percent are diagnosed. No accuracy figures, peer reviewed publications, or completed validation results were located.

No published data protection or PHI framework was located. The platform captures ocular imaging linked to patients and includes a patient facing application, and the stated continuous learning loop means clinical data feeds model improvement, so consent and data use terms are questions a buyer should resolve before deployment.

No HIPAA or BAA commitment was located. The company is Canadian and operating in Quebec clinics, where PIPEDA and provincial health privacy law govern rather than HIPAA, so a United States buyer would be establishing this from scratch.

No SOC 2, ISO 27001, or equivalent attestation was located, consistent with the company's pre commercial stage.

No FDA clearance and no Health Canada authorization were located, and the company itself describes advancing toward regulated commercialization, which is a candid acknowledgment that it is not there yet. This is the central constraint: software that produces a dry eye diagnosis and treatment recommendation is squarely within device regulation, so current deployment sits in evaluation and clinical assessment contexts rather than routine authorized care. Board expansion was explicitly framed around strengthening governance as the company advances toward regulated commercialization. Grade reflects clear disclosure of pre clearance status rather than any regulatory achievement.

No governance framework or bias evaluation was located. The independent assessment underway includes annotation quality, which touches the data foundation bias would arise from, but no analysis of performance variation across age, ethnicity, or ocular surface characteristics has been published.

No EHR integration was located. The described architecture is a clinic based imaging device with a clinician platform and a separate free patient application for pre and post visit engagement, which is a self contained stack rather than an integrated one.

No hosting, tenancy, or data residency terms were located, though the company's Canadian base and Quebec clinical deployments make residency a live question for any cross border buyer.

No prices are published, but the intended model is disclosed in outline and is unusual enough to note: an updatable application store for clinicians with pay per disease pricing, plus a free patient application for engagement and education. Pay per disease implies the platform expands beyond dry eye by adding condition modules a practice buys individually, which tells a buyer how cost will scale even without a rate.

Single condition and single specialty today: dry eye and ocular surface disease within ophthalmology and optometry clinics, addressing what the company frames as a large undiagnosed population. The pay per disease application store model signals intent to broaden into additional ocular conditions, which should be treated as roadmap. Geographic footprint is Montreal clinics with Quebec health system assessment underway, so this is not a US available product today.